# Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT03085810** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 1225 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT03085810
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-24
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 1225 (ACTUAL)
- **Why stopped:** The study was terminated earlier as the study sponsor collected sufficient data to perform all analyses as per pre-specified endpoints in the study protocol.
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03085810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03085810, "Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03085810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*